Medtech company Otivio is on a strong trajectory as it moves toward commercializing its pressure boot, Flowox, designed for multiple sclerosis (MS) patients. The company recently received CE marking for Flowox, indicating its approval for use with MS patients. Furthermore, promising results have been noted regarding the treatment of spasticity in MS patients.
Medwatch 25. september 2024 Read More »
In the second quarter of this year, Otivio raised NOK 40 million for the continued development of a ground-breaking new low risk method for symptoms management of multiple sclerosis. New investors signed for NOK 22 million, existing investors for NOK 14 million and board of directors and management the remaining NOK 4 million.
“We are very pleased to have landed the issue under the prevailing market conditions”, says Andreas Mollatt, CEO Otivio, and continues: “Realizing the values that lie in the treatment of MS symptoms is of course exciting”. “But perhaps the most motivating thing is to be able to offer people with MS a novel and low-risk method to treat these symptoms that has such a negative impact on their quality of life”.
Otivio raised NOK 40 million. Read More »
A group of five Nordic health-care companies have been awarded admission into Winston Starts, where they will receive office space, mentoring, personalized coaching and support services.
The membership is part of the Nordic AMPlify program that debuted in October 2020.
Article in Winston-Salem Journal Read More »
The Effect of 12-Week Treatment with Intermittent Negative Pressure on Blood Flow Velocity and Flowmotion, Measured with a Novel Doppler Device (Earlybird). Secondary Outcomes from a Randomized Sham-Controlled Trial in Patients with Peripheral Arterial Disease
Article in Annals of Vascular Surgery Read More »
“Norwegian healthtech company, Otivio has announced that it has extended an exploratory clinical trial with Neuro-SysMed to confirm the potential of its non-invasive FlowOx medical device to alleviate multiple sclerosis symptoms.”
Article in Hospital Hub Read More »
After Otivio came across a significant discovery for a potential new application for their device FlowOxTM 2.0, they have decided to extend their exploratory clinical trial to analyze and understand the functionality of the device for patients with Multiple Sclerosis (pwMS).
Article in Health Tech World Read More »
The Norwegian company is applying a simple physiological response to costly and tricky-to-manage conditions, its leaders told Medtech Insight.
Medtech article on Otivio’s MS Discovery Read More »
First multi-centre randomized controlled trial using FlowOx™, published in Journal of Vascular Surgery, shows improved walking capacity for patients with intermittent claudication, also known as “windows shopper’s disease”.
First RCT to show improved walking capacity Read More »
A newly published health economic study confirms that FlowOx™ therapy in combination with nominal care appears to improve the health-related quality of life (QoL) of patients when compared with standard care and may also be cost saving for payors (NHS).
Study confirms FlowOx™ cost effectiveness and improved quality of life Read More »
The doctors were about to amputate the leg of Grethe Valskaar Hetland. Then she got hold of the FlowOx boots. The FlowOx™ boot looks almost like a transparent ski-boot, or an oversized snow shoe from the 1980s.
The boots that saved Grethe’s legs Read More »
